3.9 Article

Effect of Rg3-enriched Korean red ginseng (Panax ginseng) on arterial stiffness and blood pressure in healthy individuals: a randomized controlled trial

Journal

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
Volume 8, Issue 8, Pages 537-541

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jash.2014.04.004

Keywords

Augmentation index; clinical; ginsenosides; vascular; ginseng

Funding

  1. Heart & Stroke Foundation of Ontario, Canada
  2. BTGin Co, Yuseong-gu, Daejeon, Republic of Korea

Ask authors/readers for more resources

Ginsenoside Rg3, present in steamed ginseng (Panax Ginseng C.A. Meyer), is thought to be a potent modulator of vascular function. Our objective was to clinically evaluate acute effects of ginsenoside Rg3 enriched Korean red ginseng (Rg3-KRG) on measures of arterial stiffness and peripheral and central blood pressure (BP) parameters in healthy volunteers. Using a double-blind, randomized, crossover design, 23 individuals (9 males: 14 females; age, 25 +/- 2 years; body mass index, 22 +/- 0.6 kg/m(2); systolic BP/diastolic BP, 113 +/- 3/70 +/- 2 mm Hg) were administered 400-mg Rg3-KRG extract or 400-mg wheat bran control on two separate visits with a 7-day washout period. Aortic augmentation index and central BP were measured using applanation tonometry by radial pulse wave analysis, and peripheral BP was evaluated oscillometrically. Measurements were taken at baseline and at 1, 2, and 3 hours after intervention. Compared with control, there were significant reductions in augmentation index (-4.3 +/- 8.9%, P = .03), central (-4.8 +/- 6 8 mm Hg, P = .01) and brachial mean arterial pressure (-4.4 +/- 6.6 mm Hg, P = .01), central systolic (-5.0 +/- 7.9 mm Hg, P = .01) and diastolic BP (-3.9 +/- 6.6 mm Hg, P = .01), and brachial systolic (-4.4 +/- 10.0 mm Hg, P = .048) and diastolic BP (-3.6 +/- 6 4 mm Hg, P = .01) at 3 hours after intervention compared with control. This study is the first to demonstrate Rg3-KRG extract acutely lowers central and peripheral arterial pressures in healthy adults. Further clinical evaluation is desired to quantify efficacy in higher risk individuals and in long-term settings. (C) 2014 American Society of Hypertension. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available